Why TransMedics Stock Plummeted Today

Shares of leading organ transplant platform TransMedics (NASDAQ: TMDX) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.

TransMedics issued a positive news release yesterday evening about the hiring of Gerardo Hernandez as its new chief financial officer, but one sentence at the end of the announcement seemed to spook the market.

TransMedics' tempered expectations

This final sentence reads, "TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue." This projection fell into the lower range of the company's prior guidance for $425 million to $445 million, or growth of 80% at the midpoint, prompting the market to continue reining in TransMedics' once-stretched valuation.

Following a disappointing third-quarter earnings report that saw the company only maintain market share in the transplant industry -- after growing by 10 times the market's rate in the prior year -- investors were hoping for a rebound in Q4. While the new guidance would imply a 35% sales growth rate upcoming in Q4, this is markedly lower than the triple-digit growth rates TransMedics delivered in 10 of its last 11 quarters, hence the continued sell-off.

However, with shares now down 59% from their highs, TransMedics trades at 6.3 times sales -- its lowest mark since going public in 2019. Ultimately, TransMedics remains a top dog and first mover in the organ transplant industry it is actively disrupting.

Yes, growth slowed. Nevertheless, investors must remain focused on the company's decades-long potential rather than reacting to 180 days' sales. Investors should note that TransMedics will hold an analyst day on Dec. 10, which should offer new insights and guidance going forward.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $359,445!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,374!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $484,143!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of December 2, 2024

Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.